Transcrocetinate sodium is under clinical development by Diffusion Pharmaceuticals and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Transcrocetinate sodium’s likelihood of approval (LoA) and phase transition for Hypoxia took place on 27 Jun 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Transcrocetinate sodium Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Transcrocetinate sodium overview

Transcrocetinate sodium (TSC) is under development for the treatment of chronic obstructive pulmonary disease (COPD), myocardial infarction,hypoxia, hemorrhagic shock, neurodegenerative diseases such as Alzheimer's or Parkinson's disease, acute respiratory distress syndrome (ARDS) in COVID-19 patients. The drug candidate is administered through intravenous route.  It is a new chemical entity. It was under development for peripheral arterial disease (PAD), acute ischemic stroke, pancreatic cancer and brain metastasis.

It is a synthetic small molecule carotenoid anti-oxidant.

It was under development for the treatment of newly diagnosed glioblastoma multiforme, interstitial lung diseases. The drug candidate is a radiation sensitizer. 

Diffusion Pharmaceuticals overview

Diffusion Pharmaceuticals (Diffusion), formerly Diffusion Pharmaceuticals is a clinical stage biotechnology company. It develops standard of care therapies. The company improves cancer treatments such as radiation therapy and chemotherapy in treatment-resistant solid tumors, including multiple FDA orphan-designated indications. It offers new and small-molecule drugs for regulating the movement of oxygen into tissue and treatment for stroke, treatment- resistant cancerous tumors, glioblastoma multiforme,pancreatic cancer, brain metastases. Diffusion develops trans sodium crocetinate, a synthetic small molecule that improves the diffusion of oxygen into hypoxic tissue and sensitizes the tumor to radiation therapy. The company offers products for cancer, stroke and heart attack. It performs clinical study on pancreatic cancer and brain metastasis through cancer centers. Diffusion is headquartered in Charlottesville, Virginia, the US.

Quick View Transcrocetinate sodium LOA Data

Report Segments
  • Innovator
Drug Name
  • Transcrocetinate sodium
Administration Pathway
  • Intravenous Bolus
Therapeutic Areas
  • Cardiovascular
  • Central Nervous System
  • Infectious Disease
  • Oncology
  • Respiratory
Key Developers
  • Sponsor Company: Diffusion Pharmaceuticals
  • Originator: University of Virginia
Highest Development Stage
  • Phase II


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.